Research programme: protein tyrosine phosphatase 1B inhibitors - Viracta Therapeutics
Alternative Names: Protein tyrosine phosphatase 1B inhibitors research programme – Viracta Therapeutics; PTP-1B inhibitors research programme – Viracta Therapeutics; Type-2 diabetes therapeutics research programme - Viracta TherapeuticsLatest Information Update: 02 Mar 2021
At a glance
- Originator Sunesis Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein tyrosine phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 24 Feb 2021 Sunesis Pharmaceuticals has been merged with Viracta Therapeutics to form Viracta Therapeutics
- 03 Jun 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 04 May 2007 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)